Zydus Cadila has completed enrollment in Evidences II, Evidences III and Evidences V Phase 3 clinical trials of Saroglitazar Mg for treating Non-Alcoholic SteatoHepatitis (NASH). Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico.
Evidences II is a Phase3 biopsy-driven trial of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic SteatoHepatitis. Evidences III is the prospective, multicenter, randomized, double-blind study of Saroglitazar4 mg versus Placeboin patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Evidences V will evaluate the NASH patients over a period of 18months, measure the change in the liver fat content by magnetic resonance imaging-derived proton density-fat fraction (MRIPDFF) at Week 24 and evaluate the liver biopsy driven endpoints of Saroglitazar4 mg from baseline to Week 76.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1935.25 |
| Dr. Reddys Labs. | 1245.50 |
| Cipla | 1438.75 |
| Zydus Lifesciences | 1150.50 |
| Lupin | 2496.05 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: